Table 1. Demographic and Clinical Characteristics of 41 Study Participants Across Study Time Points.
| T1 | T2 | |||
|---|---|---|---|---|
|
| ||||
| BD (n=19) | Control (n=22) | BD (n=19) | Control (n=22) | |
| Demographic characteristics | ||||
| Age in years, Mean (SD) | 16.1 (1.75) | 15.7 (1.48) | 17.3 (1.86) | 16.8 (1.40) |
| Female, n (%) | 11 (57.9) | 11 (52.4) | 11 (57.9) | 11 (52.4) |
| Caucasian, n (%) | 13 (68.4) | 12 (57.1) | 13 (68.4) | 12 (57.1) |
| Socioeconomic status, Mean (SD) | 4.68 (0.58) | 4.68 (0.58) | -- | -- |
| Pubertal development score, Mean (SD) | 3.41 (0.33) | 3.14 (0.62) | 3.53 (0.36) | 3.39 (0.48) |
| Clinical characteristics | ||||
| Current episode | ||||
| Manic/Hypomanic, n (%) | 2 (10.5) | -- | 1 (5.3) | -- |
| Depressed, n (%) | 6 (31.6) | -- | 5 (26.2) | -- |
| Mixed, n (%) | 3 (15.8) | -- | 1 (5.3) | -- |
| Inter-episode, n (%) | 8 (42.1) | -- | 12 (63.2) | -- |
| C-GAS score, Mean (SD) | 55.5 (10.5) | 93.7 (3.31) | 61.1 (9.7) | 91.1 (4.87) |
| YMRS score, Mean (SD) | 18.4 (8.15) | 0.26 (0.56) | 14.3 (9.06) | 0.75 (1.12) |
| CDRS-R score, Mean (SD) | 45.6 (16.5) | 18.2 (1.51) | 37.4 (13.3) | 19.0 (1.81) |
| Medications | ||||
| Antipsychotics, n (%) | 13 (68.4) | -- | 16 (84.2) | -- |
| Anticonvulsants, n (%) | 9 (47.4) | -- | 10 (52.6) | -- |
| SSRIs, n (%) | 8 (42.1) | -- | 7 (36.8) | -- |
| Stimulants, n (%) | 7 (36.8) | -- | 8 (42.1) | -- |
| Lithium, n (%) | 3 (15.8) | -- | 7 (36.8) | -- |
| Wellbutrin, n (%) | 2 (10.5) | -- | 3 (15.8) | -- |
| SARIs, n (%) | 2 (10.5) | -- | 0 (0) | -- |
| TCAs n (%) | 1 (5.3) | -- | 1 (5.3) | -- |
| TeCAs | 0 (0) | -- | 3 (15.8) | -- |
| Two or more classes of medications | 12 (63.2) | -- | 15 (78.9) | -- |
T1, Time 1; T2, Time 2; SD, standard deviation; Pubertal development score based on Pubertal Development Scale; C-GAS, Children's Global Assessment Scale; YMRS, Young Mania Rating Scale. CDRS-R, Child Depression Rating Scale - Revised. SSRI, selective serotonin reuptake inhibitor; SARI, serotonin antagonist reuptake inhibitor; TCA, tricyclic antidepressant; TeCA, tetracyclic antidepressant.Valid percents are reported. Two control group participants were missing YMRS scores.